Chemotherapy-induced neutropenia represents a major risk factor for infection-related ... use of G-CSF in AML only within clinical trials. 8 Pegfilgrastim is the pegylated formulation of G-CSF ...

Stimufend ® (pegfilgrastim-fpgk), a biosimilar to Neulasta ® (pegfilgrastim), has been made available by Fresenius Kabi. Stimufend, a leukocyte growth factor, is indicated to decrease the ...

Sandoz), a biosimilar to Neulasta. Ziextenzo, a leukocyte growth factor, is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid ...

IMPORTANT SAFETY INFORMATION Contraindication Contraindication Splenic Rupture G-CSF receptor has been found on tumor cell lines The possibility that pegfilgrastim products act as a growth factor ...

Who should get prophylactic myeloid growth factor is clear and unclear ... at the meeting brought up the fact that the cost of pegfilgrastim discourages its use in many patients.

Pegfilgrastim is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving ...

Indications: FYLNETRA is a leukocyte growth factor indicated to decrease the ... stimulating factors such as filgrastim products or pegfilgrastim products. Before you take FYLNETRA, tell your ...

UDENYCA® is the only pegfilgrastim brand approved in the ... INDICATIONUDENYCA® is a leukocyte growth factor indicated to: Decrease the incidence of infection, as manifested by febrile ...

G-CSF is a type of growth factor that makes bone marrow produce more white blood cells. In short, the market for pegfilgrastim is large but the competition is fierce and the ASP's (average sales ...

Pegfilgrastim is a synthetic version of granulocyte-colony stimulating factor (G-CSF) used to stimulate the production of white blood cells in patients undergoing chemotherapy. Biosimilars are ...

DOUGLAS, ISLE OF MAN, January 18, 2023 /einpresswire.com / -- Pegfilgrastim Biosimilar market Value and CAGR At a compound annual growth rate (CAGR) of 9.9%, the global pegfilgrastim biosimilars ...